A Novel Laboratory Assay to Monitor Unfractionated Heparin Dosing in Patients Taking Apixaban Prior to Hospital Admission
- 1 March 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 6 (2) , 378-386
Abstract
Introduction: When monitoring heparin, anti-Xa assays are susceptible to interference from apixaban taken before admission and can result in inappropriate dose adjustments that can negatively affect patient care. Methods: We derived a novel assay, termed corrected heparin (CH), using quantified values from a chromogenic anti-Xa assay with heparin calibrators before and after heparinase treatment to eliminate any interference from apixaban within the patient sample. We retrospectively assessed 469 specimens from 72 patients at our institution who had their unfractionated heparin infusion monitored using the CH assay because of known apixaban use. These patients were included in the study if they had detectable apixaban levels (>0.1 IU/mL by anti-Xa). Results: The analytical performance of the assay was evaluated, and precision was found to be 8.8% within 1 day and 13.3% over multiple days, with acceptable linearity (R-2 = 0.997). Evaluation of clinical performance was compared with the partial thromboplastin time (PTT), showing a lack of correlation similar to comparisons between the PTT and anti-Xa assay (Blood Coagul Fibrinolysis 1993;4:635-8). The mean time to a therapeutic result in this cohort was 10 hours and 10 minutes. The CH assay was used to determine how long the apixaban was detected by the anti-Xa assay. The majority of patients (80%) still had measurable anti-Xa assay interference from apixaban at 24 hours after the last apixaban dose. Conclusions: We have developed and evaluated an assay capable of quantifying heparin in the presence of apixaban. This assay showed acceptable performance in both analytical and clinical performance.Keywords
This publication has 14 references indexed in Scilit:
- Testing and monitoring direct oral anticoagulantsBlood, 2018
- Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical AnalysisJournal of the American Heart Association, 2018
- Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for cliniciansJournal of Thrombosis and Haemostasis, 2017
- Utilization and prescribing patterns of direct oral anticoagulantsInternational Journal of General Medicine, 2017
- Worldwide Epidemiology of Atrial FibrillationCirculation, 2014
- National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011Circulation: Cardiovascular Quality and Outcomes, 2012
- Oral Anticoagulant TherapyChest, 2012
- Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factorBlood Coagulation & Fibrinolysis, 1996
- Enzymatic elimination of heparin from plasma for activated partial thromboplastin time and prothrombin time testingBlood Coagulation & Fibrinolysis, 1993
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991